EUVIMED · CrossrefJournal
Alimentary Pharmacology & Therapeutics
ISSN 0269-2813 · Wiley
Latest articles
Issue Information
Meta‐Analysis: Fracture Risk Across the Disease Course of Coeliac Disease
Long‐Term Real‐World Switch Rates and Adherence Among Patients With Ulcerative Colitis Treated With Upadacitinib or Tumour Necrosis Factor Inhibitors
Efficacy and Predictors of Response to a Low‐FODMAP Diet in Patients With Overlap of Functional Dyspepsia and Irritable Bowel Syndrome: A Prospective Multicentre Randomized Clinical Trial
Editorial: Alcohol Use Quantification by Phosphatidylethanol in Large Steatotic Liver Disease Cohorts
Editorial: Therapeutic Drug Monitoring of Infliximab During Induction Therapy in IBD —Is This the Time for Model Informed Precision Dosing? Authors' Reply
Editorial: Where Metabolic Health Meets IBD —An Emerging Priority in Reproductive Care
Letter: Does Faecal Calprotectin Meaningfully Change Biopsy Decisions in Microscopic Colitis?
Letter: Colorectal Cancer Risk After Faecal Immunochemical Testing—Which Risk Should Guide Referral? Authors' Reply
Letter: Moving Beyond Intragastric pH in Linaprazan Glurate Development
Editorial: Objective Follow Up of Inflammation After Therapy for Eosinophilic Oesophagitis. Authors' Reply
Review Article: Cirrhosis Recompensation‐ Definition, Natural History, Clinical Implications and Considerations for Clinical Trials
Letter: Interpreting HBV Reactivation Incidence–Cohort Selection, Competing Risks and Corticosteroid Exposure
Letter: Advanced Therapies for PSC ‐ IBD : A Persistent Scarcity of Data
Carbon Footprint of Diagnostic Modalities Used in Inflammatory Bowel Disease Care: The EVERGREEN ‐ IBD Study (EVERGREEN‐IBD: Evaluating Value, Emissions, Resource Use, and GREEN diagnostics in IBD)
Letter: More Than the Sum of Its Parts—What Does ALBI Add to Interleukin‐6?
Editorial: Not All Fibres Are Created Equal—Fibre Supplements for Personalised Application. Authors' Reply
Letter: Anticoagulation After Gastrointestinal Bleeding—Prognostic Associations are not Treatment Effects
Editorial: Microscopic Colitis—Are Medications Linked to Disease or Disease Investigation?
Editorial: When It Comes to Gastrointestinal Bleeding, It's Not the Anticoagulant Therapy Itself That's the Problem, but How It's Being Managed
Editorial: Objective Follow Up of Inflammation After Therapy for Eosinophilic Oesophagitis
Letter on: ‘Impact of Prior Biologic Mechanism of Action on Anti‐ TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study’
Letter on: ‘Impact of Prior Biologic Mechanism of Action on Anti‐ TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study’. Authors' Reply
Editorial: Therapeutic Drug Monitoring of Infliximab During Induction Therapy in IBD —Is This the Time for Model Informed Precision Dosing?
Letter: Interpreting Rule‐Out and Rule‐In Enhanced Liver Fibrosis Thresholds in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Authors' Reply
Clinical Trial: Capsule Sponge as a Non‐Endoscopic Monitoring Tool in Eosinophilic Oesophagitis—A Prospective Real–World Multicentre Study
Development of a Clinical and Biomarker‐Based Score to Predict Microscopic Colitis in Patients With Chronic Watery Diarrhoea
Letter: LGP2 Q425R In Chronic Hepatitis Delta—Allele Dose, Hepatic Steatosis and Prior Interferon Exposure. Authors' Reply
Impact of Prior Biologic Mechanism of Action on Anti‐ TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study
Review Article: Fibrosis Reversal in Metabolic Dysfunction‐Associated Steatohepatitis—The Promise of Emerging Therapeutics
Volumes
2026 · 7042025 · 5942024 · 5712023 · 5002022 · 5562021 · 5252020 · 5882019 · 4932018 · 5692017 · 5122016 · 3982015 · 4242014 · 4592013 · 4332012 · 4382011 · 4002010 · 3492009 · 2902008 · 3102007 · 3812006 · 4922005 · 4252004 · 4732003 · 4052002 · 3192001 · 2642000 · 2761999 · 2741998 · 1771997 · 2031996 · 1761995 · 1101994 · 1021993 · 1111992 · 801991 · 891990 · 811989 · 711988 · 821987 · 66
EUVIMED